This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Published Erratum

. 2015 May 1;21(9):2192.

doi: 10.1158/1078-0432.CCR-15-0185.

Correction: Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors

No authors listed

PMID: 25934894
DOI: 10.1158/1078-0432.CCR-15-0185

Published Erratum

Correction: Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors

No authors listed. Clin Cancer Res. 2015.

. 2015 May 1;21(9):2192.

doi: 10.1158/1078-0432.CCR-15-0185.

PMID: 25934894
DOI: 10.1158/1078-0432.CCR-15-0185

No abstract available

PubMed Disclaimer

Erratum for

Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors.
Shapiro GI, Rodon J, Bedell C, Kwak EL, Baselga J, Braña I, Pandya SS, Scheffold C, Laird AD, Nguyen LT, Xu Y, Egile C, Edelman G. Shapiro GI, et al. Clin Cancer Res. 2014 Jan 1;20(1):233-45. doi: 10.1158/1078-0432.CCR-13-1777. Epub 2013 Oct 28. Clin Cancer Res. 2014. PMID: 24166903 Clinical Trial.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Silverchair Information Systems